W Brugger
08.11.2018
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
Griesinger F, Gautschi O, Früh M, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. Pneumologie 2018; 72:774-781.
08.11.2018[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
08.11.2018Pneumologie 2018; 72:774-781
Griesinger F, Gautschi O, Früh Martin, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J
Weiter
01.09.2000
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110:563-72.
01.09.2000Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
01.09.2000Br J Haematol 2000; 110:563-72
Möhle R, Schittenhelm Marcus, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L
Weiter